The Human Rights Campaign Foundation has initiated a class-wide legal challenge against a recent policy by the Office of Personnel Management (OPM) that curtails health-insurance coverage for gender-affirming medical care for federal employees. This policy change, set to take effect in the 2026 plan year, removes coverage for “chemical and surgical modification” related to gender transition within the Federal Employees Health Benefits (FEHB) and Postal Service Health Benefits (PSHB) programs. The challenge asserts that the exclusion is in violation of Title VII’s prohibition on sex discrimination in employment, as reported by Jurist.
Central to the filing is the claim that OPM’s policy effectively discriminates based on sex and transgender status. This exclusion targets treatments necessary for individuals with gender dysphoria, treatments which aren’t similarly restricted for other medical conditions. Furthermore, OPM’s directive includes an “exceptions process” for individuals mid-treatment, which the complaint argues is insufficiently transparent and unfairly burdensome, especially for those needing to change plans in 2026.
The filing seeks to annul Carrier Letter 2025-01b and related policy changes, aiming for a legal declaration that these exclusions are unlawful both in general and as applied to the specific complainants. Additionally, there is a push to ensure that future FEHB and PSHB plans contain no discriminatory clauses against gender-affirming care. The complainants also propose that all plan brochures include clear nondiscrimination policies related to gender identity.
The American Medical Association and other prominent medical groups support the necessity and efficacy of gender-affirming care, reinforcing the argument that the OPM’s decision denies standard treatments for transgender individuals. This legal move echoes ongoing debates surrounding healthcare rights for transgender people, which have been addressed in platforms like The Hill, where protections for these services continue to be a point of contention.
The case highlights broader implications for federal policy decisions during the Trump administration, reflecting enduring tensions in framing healthcare rights amidst evolving interpretations of sex discrimination. As federal workers challenge this directive, it underscores the continuing legal and social battles over the recognition and support of transgender healthcare needs.